Bendroflumethiazide

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Bendroflumethiazide 2.5mg;  ;  

Verfügbar ab:

Ipca Pharma (NZ) Pty Limited

INN (Internationale Bezeichnung):

Bendroflumethiazide 2.5 mg

Dosierung:

2.5 mg

Darreichungsform:

Tablet

Zusammensetzung:

Active: Bendroflumethiazide 2.5mg     Excipient: Lactose Purified talc Starch Stearic acid

Einheiten im Paket:

Blister pack, PVC/PVDC, 14 tablets

Klasse:

Prescription

Verschreibungstyp:

Prescription

Hergestellt von:

Ipca Laboratories Limited

Anwendungsgebiete:

Bendrofluazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Produktbesonderheiten:

Package - Contents - Shelf Life: Blister pack, PVC/PVDC - 14 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVDC - 28 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 500 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 1000 tablets - 24 months from date of manufacture stored at or below 25°C

Berechtigungsdatum:

2006-06-28